HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Takuji Okusaka Selected Research

Liver Diseases (Liver Disease)

2/2020Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease.
1/2019Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
2/2017Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.
7/2015Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
1/2006Multiple non-tumorous arterioportal shunts due to chronic liver disease mimicking hepatocellular carcinoma: outcomes and the associated elevation of alpha-fetoprotein.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Takuji Okusaka Research Topics

Disease

87Neoplasms (Cancer)
12/2022 - 01/2002
86Pancreatic Neoplasms (Pancreatic Cancer)
08/2022 - 01/2002
82Hepatocellular Carcinoma (Hepatoma)
09/2022 - 01/2002
38Biliary Tract Neoplasms (Biliary Tract Cancer)
06/2022 - 12/2002
16Adenocarcinoma
10/2020 - 01/2002
14Neutropenia
10/2020 - 04/2004
14Thrombocytopenia (Thrombopenia)
01/2018 - 02/2005
13Disease Progression
02/2021 - 03/2007
10Neuroendocrine Tumors (Neuroendocrine Tumor)
11/2021 - 02/2011
10Neoplasm Metastasis (Metastasis)
01/2016 - 04/2004
9Anorexia
01/2019 - 06/2006
8Hypertension (High Blood Pressure)
06/2020 - 03/2011
7Interstitial Lung Diseases (Interstitial Lung Disease)
07/2022 - 08/2010
7Ascites
03/2022 - 12/2007
7Cholangiocarcinoma
11/2020 - 11/2007
7Leukopenia
10/2020 - 02/2005
6Fibrosis (Cirrhosis)
06/2022 - 12/2010
6Carcinoma (Carcinomatosis)
11/2020 - 08/2005
6Exanthema (Rash)
01/2019 - 02/2011
5Stomach Neoplasms (Stomach Cancer)
06/2022 - 04/2014
5Gallbladder Neoplasms (Gallbladder Cancer)
08/2021 - 11/2007
5Liver Neoplasms (Liver Cancer)
10/2020 - 05/2012
5Anemia
10/2020 - 02/2011
5Liver Diseases (Liver Disease)
02/2020 - 01/2006
5Nausea
10/2018 - 06/2006
5Fatigue
01/2017 - 04/2008
5Infections
12/2016 - 09/2002
5Carcinogenesis
01/2016 - 05/2012
4Liver Cirrhosis (Hepatic Cirrhosis)
06/2022 - 02/2002
4Body Weight (Weight, Body)
01/2021 - 01/2005
4Neuroendocrine Carcinoma
01/2020 - 04/2010
3Pathologic Constriction (Stenosis)
12/2022 - 09/2020
3Hepatitis C
06/2022 - 01/2015
3Hemorrhage
07/2019 - 01/2004
3Stomatitis
01/2019 - 02/2011
3Hepatitis
01/2019 - 09/2012
3Diarrhea
12/2016 - 02/2011
3Drug-Related Side Effects and Adverse Reactions
10/2014 - 04/2005

Drug/Important Bio-Agent (IBA)

80GemcitabineFDA Link
01/2022 - 12/2002
32Cisplatin (Platino)FDA LinkGeneric
01/2022 - 01/2003
28Sorafenib (BAY 43-9006)FDA Link
01/2021 - 03/2010
22Pharmaceutical PreparationsIBA
07/2022 - 12/2002
19Fluorouracil (Carac)FDA LinkGeneric
10/2018 - 02/2002
16Biomarkers (Surrogate Marker)IBA
06/2022 - 11/2005
14Proteins (Proteins, Gene)FDA Link
03/2022 - 01/2011
12Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2019 - 11/2002
11RamucirumabIBA
06/2020 - 07/2015
8lenvatinibIBA
09/2022 - 03/2016
8Alanine Transaminase (SGPT)IBA
06/2017 - 02/2005
7folfirinoxIBA
08/2022 - 10/2014
7PlatinumIBA
10/2020 - 04/2004
7alpha-Fetoproteins (alpha-Fetoprotein)IBA
06/2020 - 01/2006
6Peptides (Polypeptides)IBA
01/2021 - 12/2009
6Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2020 - 02/2011
6BilirubinIBA
10/2019 - 04/2004
6ProteomeIBA
02/2012 - 11/2005
6TegafurIBA
03/2011 - 01/2002
5Antineoplastic Agents (Antineoplastics)IBA
07/2022 - 05/2015
5Tyrosine Kinase InhibitorsIBA
01/2022 - 02/2011
5EverolimusFDA Link
11/2021 - 02/2011
5Protein Subunit VaccinesIBA
01/2021 - 12/2010
5Monoclonal AntibodiesIBA
01/2021 - 05/2014
5Epirubicin (Ellence)FDA LinkGeneric
02/2018 - 01/2003
5DNA (Deoxyribonucleic Acid)IBA
01/2017 - 01/2007
5EnzymesIBA
11/2015 - 09/2004
5UracilIBA
03/2011 - 01/2002
4Biological ProductsIBA
12/2020 - 09/2002
4Irinotecan (Camptosar)FDA LinkGeneric
10/2018 - 03/2007
4miriplatinIBA
02/2018 - 04/2004
4C-Reactive ProteinIBA
01/2016 - 01/2009
4Ethiodized Oil (Ethiodol)FDA Link
01/2014 - 01/2002
4S 1 (combination)IBA
01/2013 - 12/2010
3Serum AlbuminIBA
06/2022 - 11/2002
3GlypicansIBA
01/2021 - 04/2014
3Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2021 - 03/2011
3130-nm albumin-bound paclitaxelIBA
01/2021 - 10/2018
3Axitinib (AG 013736)IBA
01/2021 - 03/2011
3LigandsIBA
01/2021 - 01/2011
3Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2020 - 01/2018
3Sunitinib (Sutent)FDA Link
06/2019 - 10/2013
3Fetal Proteins (Fetoprotein)IBA
01/2019 - 01/2015
3Immune Checkpoint InhibitorsIBA
01/2019 - 01/2018
3Streptozocin (Streptozotocin)FDA Link
10/2018 - 07/2015
3Mitoxantrone (Novantrone)FDA LinkGeneric
06/2017 - 02/2005
3Hepatitis B Surface Antigens (HBsAg)FDA Link
12/2016 - 09/2012
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2015 - 03/2011
3Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
07/2015 - 02/2011
3(2E,4E,6E,10E)- 3,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acidIBA
06/2015 - 06/2011
3Transaminases (Aminotransferases)IBA
02/2015 - 01/2005
3orantinib (SU6668)IBA
10/2014 - 02/2011

Therapy/Procedure

98Drug Therapy (Chemotherapy)
06/2022 - 01/2002
75Therapeutics
09/2022 - 12/2002
13Radiotherapy
01/2021 - 06/2003
11Combination Drug Therapy (Combination Chemotherapy)
01/2022 - 01/2005
9Chemoradiotherapy
02/2021 - 01/2004
8Stents
12/2022 - 10/2014
3Self Expandable Metallic Stents
12/2022 - 01/2021
3Choledochostomy
04/2022 - 01/2021
3Adjuvant Chemotherapy
10/2018 - 09/2012
3Immunotherapy
01/2018 - 12/2009